Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2007-4-17
pubmed:abstractText
Accumulation of hyaluronan has been demonstrated in the peritumoral breast cancer stroma and nests of tumor cells. In this study, we have quantified the production of hyaluronan and the expression of mRNAs encoding hyaluronan synthesizing (HAS) and hyaluronan degrading (HYAL) enzymes in a panel of breast cancer cell lines. The analysis revealed that highly invasive breast cancer cells produce high amounts of hyaluronan and express preferentially HAS2 mRNA, whereas less invasive breast cancer cells produce low amount of hyaluronan and express HAS1 and HYAL1 mRNAs. We explored the importance of HAS2 expression for breast cancer tumorigenicity, by specifically silencing the HAS2 gene using RNA interference (RNAi)-mediated suppression in the invasive breast cancer cell line Hs578T. This led to a less aggressive phenotype of the breast tumor cells, as assessed by cell growth, both in anchorage-dependent and anchorage-independent cultures. siRNA-mediated knock down of HAS2 in Hs578T breast tumor cells led to an up-regulation of HAS1, HAS3 and HYAL1 mRNAs, resulting in only a 50% decrease in the net hyaluronan production; however, the synthesized hyaluronan was of lower size and more polydisparse compared to control siRNA-treated cells. Interestingly, Hs578T cells deprived of HAS2 migrated only half as efficiently as HAS2 expressing cells through cell-free areas in a culture wounding assay and through Transwell polycarbonate membrane as well as invaded a Matrigel layer. These results imply that alterations in HAS2 expression and endogenously synthesized hyaluronan affect the malignant phenotype of Hs578T breast cancer cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0020-7136
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2557-67
pubmed:dateRevised
2007-7-24
pubmed:meshHeading
pubmed-meshheading:17315194-Breast Neoplasms, pubmed-meshheading:17315194-Cell Cycle, pubmed-meshheading:17315194-Cell Line, Tumor, pubmed-meshheading:17315194-Cell Movement, pubmed-meshheading:17315194-Cell Proliferation, pubmed-meshheading:17315194-Gene Expression Regulation, Enzymologic, pubmed-meshheading:17315194-Gene Expression Regulation, Neoplastic, pubmed-meshheading:17315194-Glucuronosyltransferase, pubmed-meshheading:17315194-Humans, pubmed-meshheading:17315194-Hyaluronic Acid, pubmed-meshheading:17315194-Hyaluronoglucosaminidase, pubmed-meshheading:17315194-Isoenzymes, pubmed-meshheading:17315194-Neoplasm Invasiveness, pubmed-meshheading:17315194-Protein Binding, pubmed-meshheading:17315194-RNA, Messenger, pubmed-meshheading:17315194-RNA, Small Interfering, pubmed-meshheading:17315194-RNA Interference, pubmed-meshheading:17315194-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17315194-Transfection
pubmed:year
2007
pubmed:articleTitle
Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells.
pubmed:affiliation
Ludwig Institute for Cancer Research, Uppsala University, Box 595, Biomedical Center, Uppsala, Sweden.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't